跳转至内容
Merck
CN
  • A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.

A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.

The Journal of pathology (2014-10-29)
Brian W Simons, Nicholas M Durham, Tullia C Bruno, Joseph F Grosso, Anthony J Schaeffer, Ashley E Ross, Paula J Hurley, David M Berman, Charles G Drake, Praveen Thumbikat, Edward M Schaeffer
摘要

Inflammation is associated with several diseases of the prostate including benign enlargement and cancer, but a causal relationship has not been established. Our objective was to characterize the prostate inflammatory microenvironment after infection with a human prostate-derived bacterial strain and to determine the effect of inflammation on prostate cancer progression. To this end, we mimicked typical human prostate infection with retrograde urethral instillation of CP1, a human prostatic isolate of Escherichia coli. CP1 bacteria were tropic for the accessory sex glands and induced acute inflammation in the prostate and seminal vesicles, with chronic inflammation lasting at least 1 year. Compared to controls, infection induced both acute and chronic inflammation with epithelial hyperplasia, stromal hyperplasia, and inflammatory cell infiltrates. In areas of inflammation, epithelial proliferation and hyperplasia often persist, despite decreased expression of androgen receptor (AR). Inflammatory cells in the prostates of CP1-infected mice were characterized at 8 weeks post-infection by flow cytometry, which showed an increase in macrophages and lymphocytes, particularly Th17 cells. Inflammation was additionally assessed in the context of carcinogenesis. Multiplex cytokine profiles of inflamed prostates showed that distinct inflammatory cytokines were expressed during prostate inflammation and cancer, with a subset of cytokines synergistically increased during concurrent inflammation and cancer. Furthermore, CP1 infection in the Hi-Myc mouse model of prostate cancer accelerated the development of invasive prostate adenocarcinoma, with 70% more mice developing cancer by 4.5 months of age. This study provides direct evidence that prostate inflammation accelerates prostate cancer progression and gives insight into the microenvironment changes induced by inflammation that may accelerate tumour initiation or progression.

材料
货号
品牌
产品描述

Sigma-Aldrich
盐酸, ACS reagent, 37%
Sigma-Aldrich
盐酸 溶液, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
盐酸, 36.5-38.0%, BioReagent, for molecular biology
Sigma-Aldrich
抗层粘连蛋白 兔抗, 0.5 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
盐酸, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., fuming, ≥37%, APHA: ≤10
Sigma-Aldrich
乙二胺四乙酸 溶液, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
盐酸, meets analytical specification of Ph. Eur., BP, NF, fuming, 36.5-38%
Sigma-Aldrich
乙二胺四乙酸, ACS reagent, 99.4-100.6%, powder
Supelco
盐酸 溶液, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
乙二胺四乙酸, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
乙二胺四乙酸 二钠盐 溶液, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O
Sigma-Aldrich
乙二胺四乙酸, 99.995% trace metals basis
Sigma-Aldrich
乙二胺四乙酸, anhydrous, BioUltra, ≥99% (titration)
Sigma-Aldrich
盐酸 溶液, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
乙二胺四乙酸, purified grade, ≥98.5%, powder
Sigma-Aldrich
盐酸 溶液, 32 wt. % in H2O, FCC
Sigma-Aldrich
氯化氢 溶液, 1.0 M in diethyl ether
Supelco
氯化氢 – 甲醇 溶液, ~1.25 m HCl (T), for GC derivatization, LiChropur
Sigma-Aldrich
盐酸, puriss., 24.5-26.0%
Sigma-Aldrich
氯化氢 溶液, 1.0 M in acetic acid
Sigma-Aldrich
乙二胺四乙酸, ≥98.0% (KT)
Supelco
氯化氢 – 乙醇 溶液, ~1.25 M HCl, for GC derivatization, LiChropur
Supelco
氯化氢 – 2-丙醇 溶液, ~1.25 M HCl (T), for GC derivatization, LiChropur
Sigma-Aldrich
乙二胺四乙酸, BioUltra, ≥99.0% (KT)
Sigma-Aldrich
乙二胺四乙酸, Vetec, reagent grade, 98%